Conference Coverage

Low serum AMH predicted miscarriage after IVF


– Low serum levels of anti-Müllerian hormone predicted miscarriage after in vitro fertilization and embryo transfer, according to a single-center prospective study of more than 2,000 women.


The study comprised 2,365 women undergoing 2,688 IVF cycles with fresh oocytes. Levels of AMH were measured by ELISA (AMH Gen II, Beckman Coulter) within 12 months before IVF on cycle days 2 and 4, said Dr. Tarasconi of University of Paris Ouest in France.

Women younger than 34 years old, women 34-36 years old, and women 37 years and older had the highest rates of miscarriage when they had low serum AMH levels. For the two older age groups, low AMH was associated with about a 33% miscarriage rate – about twice the rate of miscarriage among women whose AMH measured at least 5.6 ng per mL. This difference reached statistical significance for both age groups (P less than .05).

Among women younger than 34 years, low serum AMH was associated with a 22% rate of miscarriage, compared with about 13% among women with higher AMH levels. This difference did not reach significance because of a lack of power, Dr. Tarasconi said. “However, binary logistic regression of the whole population confirmed the association between low serum AMH and miscarriage, independent of patient’s age and oocyte yield, with the P value less than .001.”

Low circulating AMH can reflect an above-average prevalence of oocyte abnormalities, which are linked to miscarriage, Dr. Tarasconi noted. “The fact that oocyte yield failed to alter the relationship between AMH and miscarriage suggests that altered per-follicle AMH production, not oocyte or embryo availability, fosters pregnancy loss,” he added. However, the researchers did not test either preimplantation embryos or the expelled gestational sacs to directly link miscarriages to abnormalities such as aneuploidy, he noted.

Low AMH levels also were associated with lower rates of pregnancy after IVF, regardless of age, as has been previously reported. Patients in the study were of normal karyotype, with no history of recurrent pregnancy loss, uterine abnormalities, or family history of genetic or congenital disorders, Dr. Tarasconi noted.

He reported having no financial disclosures.

Recommended Reading

Early days of IVF marked by competition, innovation
MDedge ObGyn
Triptorelin doesn’t prevent ovarian failure in young women treated for lymphoma
MDedge ObGyn
Oocyte donation may up risk of preterm birth
MDedge ObGyn
European Commission’s proposed criteria for endocrine disruptors trigger multiple concerns
MDedge ObGyn
Unexplained subfertility in RA linked to periconceptional NSAID use
MDedge ObGyn